Insulin resistance (IR) precedes diabetes in a state called prediabetes. When tissues become resistant to insulin, the pancreatic beta cells produces more insulin to adjust to the need of the organism. When the pancreatic beta cells are overused, they exhaust, and the blood glucose concentration is not anymore properly regulated leading to type II diabetes (T2D).
The management of type II diabetes starts with hygienic recommendations such as physical activity and healthy diet. Then, hyperglycemia is addressed with numerous drugs but none of them are fully efficient in the long term and many have side effects. Moreover, they do not prevent the development of IR, the pathophysiological stage preceding T2D for which no molecule has a market authorization.
Solution brought by ALF-5755
THAC develops ALF-5755 with type II diabetes as first indication (patent WO2014/167230). In mouse models of this disease, ALF-5755 has demonstrated its efficacy :
THAC has a collaboration with the University of Paris (UMR 8251) directed by Pr. C. Magnan to complete the preclinical studies on animal models of type II diabetes prior to start the clinical phases